Visceral and nebulous predictions are why we are here - LymPro L-002 test data is overdue - a failure to diver next week on this critical Milestone - and the Street will take us apart - like a fine tune mechanic. There is a general malaise and sense of mistrust being evidenced here with the share price at $0.088 - and for good reason. That said, I'm looking for the CEO to do his job, back up his words and deliver the goods - is all.